CanSino Biologics Inc.
HKSE: 6185.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Xuefeng Yu
- Employees
- 1,105
- Headquarters
- Tianjin, China
- IPO year
- 2019
- Market cap
- HK$10.8B
- Website
- https://www.cansinotech.com
Loading 6185…
Loading profile data…Frequently asked questions about 6185
What does CanSino Biologics Inc. (6185.HK) do?
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP...
Where does 6185.HK trade?
CanSino Biologics Inc. (6185.HK) trades on the Hong Kong Stock Exchange.
What sector is 6185.HK in?
CanSino Biologics Inc. (6185.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of CanSino Biologics Inc.?
Xuefeng Yu is the chief executive officer of CanSino Biologics Inc. (6185.HK).
Where is CanSino Biologics Inc. headquartered?
CanSino Biologics Inc. is headquartered in China.
Does 6185.HK pay a dividend?
CanSino Biologics Inc. (6185.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6185.HK go public?
CanSino Biologics Inc. (6185.HK) completed its initial public offering in 2019.